Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

Eiji Iwama, Yoichi Nakanishi, Isamu Okamoto

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have a pronounced clinical benefit for patients with advanced non–small cell lung cancer (NSCLC) positive for EGFR activating mutations. Such individuals inevitably develop resistance to these drugs, however, new treatment strategies to overcome such resistance are being actively pursued. The clinical benefit of EGFR-TKIs for patients with locally advanced NSCLC remains to be clarified. Areas covered: This review summarizes the recent progress in combination treatment with EGFR-TKIs and either chemotherapy or radiotherapy for patients with NSCLC positive for EGFR activating mutations. Expert commentary: Combination therapy with EGFR-TKIs and various other treatment options are under investigation in clinical studies. Although early studies failed to show a clinical benefit for such combination therapy because of a lack of patient selection, clinical studies with patient selection based on EGFR mutation status have shown promising results. Such combination therapy might eventually replace the current standard treatment for patients with NSCLC positive for EGFR activating mutations.

Original languageEnglish
Pages (from-to)267-276
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 4 2018

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Mutation
Therapeutics
Patient Selection
Drug Resistance
Radiotherapy
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer. / Iwama, Eiji; Nakanishi, Yoichi; Okamoto, Isamu.

In: Expert Review of Anticancer Therapy, Vol. 18, No. 3, 04.03.2018, p. 267-276.

Research output: Contribution to journalReview article

@article{6b72f2f2aca54da9838507a64051f6fe,
title = "Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer",
abstract = "Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have a pronounced clinical benefit for patients with advanced non–small cell lung cancer (NSCLC) positive for EGFR activating mutations. Such individuals inevitably develop resistance to these drugs, however, new treatment strategies to overcome such resistance are being actively pursued. The clinical benefit of EGFR-TKIs for patients with locally advanced NSCLC remains to be clarified. Areas covered: This review summarizes the recent progress in combination treatment with EGFR-TKIs and either chemotherapy or radiotherapy for patients with NSCLC positive for EGFR activating mutations. Expert commentary: Combination therapy with EGFR-TKIs and various other treatment options are under investigation in clinical studies. Although early studies failed to show a clinical benefit for such combination therapy because of a lack of patient selection, clinical studies with patient selection based on EGFR mutation status have shown promising results. Such combination therapy might eventually replace the current standard treatment for patients with NSCLC positive for EGFR activating mutations.",
author = "Eiji Iwama and Yoichi Nakanishi and Isamu Okamoto",
year = "2018",
month = "3",
day = "4",
doi = "10.1080/14737140.2018.1432356",
language = "English",
volume = "18",
pages = "267--276",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

AU - Iwama, Eiji

AU - Nakanishi, Yoichi

AU - Okamoto, Isamu

PY - 2018/3/4

Y1 - 2018/3/4

N2 - Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have a pronounced clinical benefit for patients with advanced non–small cell lung cancer (NSCLC) positive for EGFR activating mutations. Such individuals inevitably develop resistance to these drugs, however, new treatment strategies to overcome such resistance are being actively pursued. The clinical benefit of EGFR-TKIs for patients with locally advanced NSCLC remains to be clarified. Areas covered: This review summarizes the recent progress in combination treatment with EGFR-TKIs and either chemotherapy or radiotherapy for patients with NSCLC positive for EGFR activating mutations. Expert commentary: Combination therapy with EGFR-TKIs and various other treatment options are under investigation in clinical studies. Although early studies failed to show a clinical benefit for such combination therapy because of a lack of patient selection, clinical studies with patient selection based on EGFR mutation status have shown promising results. Such combination therapy might eventually replace the current standard treatment for patients with NSCLC positive for EGFR activating mutations.

AB - Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have a pronounced clinical benefit for patients with advanced non–small cell lung cancer (NSCLC) positive for EGFR activating mutations. Such individuals inevitably develop resistance to these drugs, however, new treatment strategies to overcome such resistance are being actively pursued. The clinical benefit of EGFR-TKIs for patients with locally advanced NSCLC remains to be clarified. Areas covered: This review summarizes the recent progress in combination treatment with EGFR-TKIs and either chemotherapy or radiotherapy for patients with NSCLC positive for EGFR activating mutations. Expert commentary: Combination therapy with EGFR-TKIs and various other treatment options are under investigation in clinical studies. Although early studies failed to show a clinical benefit for such combination therapy because of a lack of patient selection, clinical studies with patient selection based on EGFR mutation status have shown promising results. Such combination therapy might eventually replace the current standard treatment for patients with NSCLC positive for EGFR activating mutations.

UR - http://www.scopus.com/inward/record.url?scp=85042351253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042351253&partnerID=8YFLogxK

U2 - 10.1080/14737140.2018.1432356

DO - 10.1080/14737140.2018.1432356

M3 - Review article

C2 - 29363369

AN - SCOPUS:85042351253

VL - 18

SP - 267

EP - 276

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 3

ER -